Parkman Healthcare Partners Llc
- Regulatory AUM
- $1.7B
- Discretionary
- $1.7B
- Clients
- 7
- Avg AUM / client
- $249M
- Accounts
- 7
- Employees
- 12
AUM over time
Reported AUM from Form ADV filings, plotted by filing date · as of Mar 27, 2026
Investments (13F portfolio — 90 positions, $969,641,007)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Stryker Corporation | COM | $50,856,203 | 154,771 | 5.24% | 2.92% |
| 2 | Dexcom Inc | COM | $43,320,822 | 689,822 | 4.47% | 2.48% |
| 3 | Kalvista Pharmaceuticals Inc | COM | $36,948,736 | 1,835,506 | 3.81% | 2.12% |
| 4 | Insulet Corp | COM | $32,852,760 | 156,561 | 3.39% | 1.88% |
| 5 | Eli Lilly & Co | COM | $31,838,758 | 34,616 | 3.28% | 1.83% |
| 6 | Ptc Therapeutics Inc | COM | $29,388,829 | 431,364 | 3.03% | 1.69% |
| 7 | Xenon Pharmaceuticals Inc | COM | $28,902,585 | 497,035 | 2.98% | 1.66% |
| 8 | Boston Scientific Corp | COM | $28,160,192 | 448,768 | 2.9% | 1.61% |
| 9 | Cvs Health Corp | COM | $27,816,317 | 387,306 | 2.87% | 1.59% |
| 10 | Arcus Biosciences Inc | COM | $26,077,118 | 1,207,274 | 2.69% | 1.5% |
| 11 | Livanova Plc | SHS | $25,676,015 | 403,965 | 2.65% | 1.47% |
| 12 | Zimmer Biomet Holdings Inc | COM | $24,373,344 | 269,557 | 2.51% | 1.4% |
| 13 | Mbx Biosciences Inc | COM | $23,881,104 | 800,037 | 2.46% | 1.37% |
| 14 | Ani Pharmaceuticals Inc | COM | $21,576,218 | 280,575 | 2.23% | 1.24% |
| 15 | Syndax Pharmaceuticals Inc | COM | $21,059,297 | 901,511 | 2.17% | 1.21% |
| 16 | Qiagen Nv | ORD SHARES | $20,020,000 | 500,000 | 2.06% | 1.15% |
| 17 | Envista Holdings Corporation | COM | $18,055,651 | 711,693 | 1.86% | 1.04% |
| 18 | Eyepoint Inc | COM NEW | $17,463,372 | 1,354,800 | 1.8% | 1.0% |
| 19 | Abbvie Inc | COM | $16,311,750 | 75,000 | 1.68% | 0.94% |
| 20 | Biocryst Pharmaceuticals Inc | COM | $16,261,102 | 1,708,099 | 1.68% | 0.93% |
| 21 | Iqvia Hldgs Inc | COM | $14,786,159 | 86,702 | 1.52% | 0.85% |
| 22 | Agios Pharmaceuticals Inc | COM | $13,651,251 | 403,525 | 1.41% | 0.78% |
| 23 | Illumina Inc | COM | $13,604,206 | 110,370 | 1.4% | 0.78% |
| 24 | Edwards Lifesciences Corp | COM | $13,385,772 | 167,155 | 1.38% | 0.77% |
| 25 | Neurocrine Biosciences Inc | COM | $13,051,350 | 99,069 | 1.35% | 0.75% |
Top 25 of 90 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 7 | $1.7B | 100.0% |
Private funds (2)
Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $362M combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Parkman Hp Master Fund Lp master | Hedge Fund | Cayman Islands | $356M | 39 |
| Parkman Venture Partners Spv I Lp | Private Equity Fund | Delaware | $6.0M | 12 |
People (1)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Martinez, Gregory, Arthur | Chief Investment Officer | Nov 2018 (8y) | 50% – 75% of Parkman Healthcare Partners Holdings Lp (indirect) |
Entity owners (Schedule A/B)
| Entity | Title / status | Since | Sch. | Ownership |
|---|---|---|---|---|
| Parkman Healthcare Partners Holdings Gp Llc | General Partner | Mar 2019 | B | GP / trustee / elected manager of Parkman Healthcare Partners Holdings Lp (indirect) |
Undisclosed: 95% – 100% of the firm is not attributable from the filed Schedule A bands.
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (2, $362M gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Parkman Hp Master Fund Lp | Hedge Fund | $356M | $1.0M | 39 |
| Parkman Venture Partners Spv I Lp | Private Equity Fund | $6.0M | $100K | 12 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/27/2026 | 1.24 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports it does not have custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 27, 2026.
View current Form ADV (SEC/IAPD) ↗